Content Type: Article

  • SEC Releases a Second Installment of “Bad Actor” Rule Guidance

    SEC Releases a Second Installment of “Bad Actor” Rule Guidance

    ARTICLE / CLIENT ALERT

    SEC Releases a Second Installment of “Bad Actor” Rule Guidance

    January 22, 2014

    Read time: 22 min

    Key takeaways
    Overview

    Earlier this month, the Division of Corporate Finance (“CorpFin”) of the U.S. Securities and Exchange Commission supplemented — for the second time[1] — its Compliance and Disclosure Interpretations (“C&DIs”)[2] to address some of the questions raised by private fund managers (and others) regarding the “bad actor” disqualification provisions of Rule 506(d).[3]

    New Rule 506(d), which became effective on Sept. 23, 2013, disqualifies issuers that have committed or experienced (or who have a relationship with certain categories of persons who have committed or experienced) one or more of an enumerated list of bad acts and actions from relying on the exemption from registration under the Securities Act of 1933 provided by Rule 506 of Regulation D. However, the final text of the rule and the adopting release[4] raised a number of questions on how certain provisions of the bad actor rule would be interpreted in the context of private funds.

    Details of the New SEC Staff Guidance

    By issuing these new C&DIs, CorpFin has taken another substantial step toward resolving the points of confusion and uncertainty that continue to surround Rule 506(d). These new interpretations address the following points:

    • Defining “beneficial owner” for purposes of Rule 506(d) 
      Under Rule 506(d), an issuer is disqualified from relying on Regulation D if “any beneficial owner of 20% or more of the issuer’s outstanding voting equity securities, calculated on the basis of voting power” is a bad actor (as described in the rule). However, neither the text of the rule nor the adopting release contained a definition of “beneficial owner” or “beneficial ownership,”[5] which resulted in some confusion in the marketplace.Question 260.29 asks whether the term “beneficial owner,” as used in Rule 506(d), is to be interpreted the same way as that term is used under Exchange Act Rule 13d-3.  The answer is an unambiguous “Yes,” and the C&DI goes on to expressly state that:

    “beneficial owner” under Rule 506(d) means any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, under Exchange Act Rule 13d-3 has or shares, or is deemed to have or share: (1) voting power, which includes the power to vote, or to direct the voting of, such security; and/or (2) investment power, which includes the power to dispose, or to direct the disposition of, such security.

    • Addressing the “look through” issue for beneficial owner determinations under Rule 506(d)
      Question 260.30 follows with guidance on whether a “look through” to “controlling persons” is required, and it states that “[b]eneficial ownership includes both direct and indirect interests, determined as under Exchange Act Rule 13d-3.”
    • Applying the Section 13(d) “group” theory to Rule 506(d) beneficial owners
      CorpFin continued its application of the Rule 13d-3 definition of beneficial owner to Rule 506(d) in Question 260.31, providing guidance that the interests held by beneficial owners of voting securities who comprise a “group” are to be aggregated. Using the example of a voting agreement among shareholders, the staff demonstrated how the application of Section 13(d) and Rule 13d can result in the group itself having the status of a single beneficial owner that is deemed to beneficially own all of the securities owned by the group members, while the group members are only deemed to beneficially own those securities over which each actually has voting or investment power.
    • Clarifying the post hoc timing of the Rule 506(d) beneficial owner test
      In Question 260.28, CorpFin clarified that a shareholder or investor is not covered by 506(d) as a 20% beneficial owner until after the transaction that makes it a 20% beneficial owner closes. In other words, a bad actor can complete a purchase that brings its interest in the issuer’s outstanding voting securities over 20% and that transaction can be in compliance with Rule 506 of Regulation D, but the issuer will be disqualified from conducting subsequent placements under Rule 506 while that bad actor is a 20% or greater beneficial owner of the issuer’s outstanding voting securities.

    Specific C&DI Guidance on Rule 506(e)

    In addition to the beneficial owner guidance discussed above, one C&DI, Question 260.32, focuses on whether a court or regulator determination that would otherwise, pursuant to Rule 506(d)(2)(iii), negate an issuer’s Rule 506 ineligibility can also nullify the disclosure obligation set forth in Rule 506(e).[6]

    The new C&DI clarifies that – with respect to pre-Sept. 23, 2013 acts or events of the kind enumerated in Rule 506(d) – an order of a court or regulator, even if it satisfies Rule 506(d)(2)(iii), cannot eliminate the Rule 506(e) notice obligation.  CorpFin, however, did clarify that a regulatory authority could determine that an order entered before Sept. 23, 2013 would not have triggered disqualification because it was not covered by Rule 506(d)(1) (i.e., “because the violation was not a final order based ona violation of any law or regulation that prohibits fraudulent, manipulative, or deceptive conduct entered within ten years before such sale” (emphasis added)).

    Certain Implications of the Beneficial Owner Guidance

    The C&DIs on the beneficial owner issue effectively require that private fund managers become intimately familiar with Section 13(d) and Rule 13d-3. By definitionally linking to Rule 13d-3, the CorpFin guidance provides a construct for determining the proper Rule 506(d) treatment of several common situations faced by private fund managers, including the following:

    • Advisers to multiple investors
      Managers who have or share “voting power” or “investment power” over an investing entity (e.g., an investment adviser to a fund of funds) may be deemed under Rule 13d-3 to be the beneficial owner of that investing entity’s positions. While every situation is different and a careful examination of the particular facts is required, if a manager has voting or investment power over two or more entities or accounts, then the manager should consider whether it would be deemed to be the beneficial owner of all of the various investments. This kind of conclusion could result, for example, in an adviser to two separate 12% holders of record being deemed, under Rule 13d-3, to have beneficial ownership of an aggregate 24% position.
    • Corporate entity investors
      Beneficial ownership of the holdings of a corporation (or a similar structure for other forms of organization) can sometimes be deemed to be held solely by the corporation itself. The shareholders of a corporation generally are not deemed to be the beneficial owners of the securities held by the corporation because they typically do not have voting or investment power over the securities held by the corporation, although there are some exceptions to this general rule (such as in the case of a corporation’s controlling shareholder(s)). Where a board of directors or other group of persons has voting or investment power over the securities held by the corporation, depending on the facts, the individual members of the board or other group may be deemed not to have voting or investment power over the securities and therefore not be deemed to be beneficial owners.[7] Accordingly, there may often be no need to look-through to individual directors or to shareholders of a corporation.
    • Investing partnerships 
      Many partnerships that make investments deem the general partner to have the Section 13(d) beneficial ownership of the partnership’s positions; provided that the limited partners have no voting or investment power over the partnership’s positions.
    • Trusts and endowments 
      Trusts and endowments must also be analyzed on a case-by-case basis. Some trusts and endowments will more closely resemble partnerships, while others will have a structure akin to a corporation; this structural distinction can result in very different outcomes in terms of Rule 13d-3 beneficial ownership.

    Broader Guidance on the “Group” Concept under Section 13(d) and 13(g)

    As noted above, the new bad actor C&DIs expressly apply the Section 13(d) “group” concept to Rule 506(d). Question 260.31 makes clear that an issuer can be disqualified from reliance on Rule 506 if: (i) a group beneficially owning a 20% or greater position is itself a bad actor or (ii) a member of a 20% group who is a bad actor is deemed to beneficially own the securities held by the other group members such that the member is itself a 20% or greater beneficial owner. 

    CorpFin provided, through the combination of Question 260.31 and a concurrent update to another set of C&DIs on “Exchange Act Sections 13(d) and 13(g) and Regulation 13D-G Beneficial Ownership Reporting,” new guidance clarifying when an individual group member’s bad actor status will be deemed to be a disqualifying condition. In Question 105.06 of the Section 13(d) C&DIs, CorpFin stated that an individual group member would be deemed to have beneficial ownership of the securities held by the other group members in situations where the agreement among them gives that individual member voting or investment power over the securities held by the other group members, such as where a member holds a bona fide irrevocable proxy or the right to designate a director for whom the other group members must vote (and not merely because it is a member of the group). If such a group agreement gives a bad actor beneficial ownership over 20% or more of an issuer’s outstanding voting securities, the group agreement will result in a disqualifying condition.

    Certain Considerations for Private Fund Managers

    CorpFin’s strong and unambiguous application of the Rule 13d-3 “group” concept does not necessarily mean that a manager needs to obtain bad actor representations from every single investor. It may, however, be useful to obtain representations from (or perform some other kind of “reasonable care” diligence on) groups of investors (e.g., private banking “platform” clients, managed accounts, or funds of funds) that share a common adviser and that collectively hold a position that approaches (or exceeds) 20% of a fund’s equity voting securities. If a decision is made to obtain a representation, it should cover the investor of record as well as any other person that, through the investor of record, would be deemed a Rule 13d-3 beneficial owner of 20% or more of the issuer’s outstanding voting securities.

    In addition, given the clarification in Question 260.32, private fund managers should confirm with their placement agents (potentially among others) that there are no additional pre-Sept. 23 events that should be disclosed. Given the guidance provided in Question 260.23 (discussed in our earlier alert),[8] issuers may need to provide supplementary disclosure to investors or consider taking other steps to satisfy “reasonable care” if a placement agent (or other covered person) previously was taking a position regarding a prior sanction or order that is not consistent with new C&DI Question 260.32.

    Remaining Open Issues

    The two rounds of C&DIs have addressed many, but not all, of the uncertainty surrounding Rule 506(d). We are working with many market participants in seeking additional guidance and will keep our clients informed of any new developments.

    Authored by Brian T. Daly, Marc E. Elovitz, Eleazer Klein and Adriana Schwartz.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] We addressed the first (Dec. 3, 2013) round of bad actor C&DIs in an earlier Alert titled SEC Releases Additional “Bad Actor” Rule Guidance .

    [2] The C&DIs, generally presented in a question-and-answer format, comprise a publicly available source of Division guidance on certain issues raised by the rules promulgated by the SEC under the Securities Act of 1933. They are subject to revision from time to time and will often also contain an indicator of the latest date of publication or revision.

    [3] The new C&DIs are Questions 260.28 through 260.32 and can be found on the SEC website. This Alert provides a short summary of these C&DIs and, in addition, we have appended them, in full text, to this Alert as Appendix 1. We also append the full text of the December 2013 C&DIs (Questions 260.14 through 260.27) to this Alert as Appendix 2.

    [4] Release No. 33-9414, Disqualification of Felons and Other “Bad Actors” from Rule 506 Offerings (July 10, 2013)

    [5] Footnote 280 to the adopting release, which spoke about “beneficial ownership reports,” implied that a Rule 13d-3 definition would apply, which the new C&DIs have now confirmed and clarified.

    [6] Rule 506(d)(2)(iii) permits issuers to rely on a written determination from a disciplining court or regulatory authority that a relevant sanction resulting from a disqualifying event that occurred on or after Sept. 23, 2013 should not result in a Rule 506 disqualification. Rule 506(e), on the other hand, requires issuer disclosure of disqualifying events that would have triggered disqualification, except that these events occurred before Sept. 23, 2013.

    [7] See, for example, the so-called “rule of three” no-action letter (which concluded that where voting and investment decisions regarding a trust’s portfolio securities are made by three or more trustees, and voting or investment decisions require the approval of a majority of those trustees, none of the individual trustees are deemed a beneficial owner of the trust’s portfolio securities) (Southland Corp. (July 8, 1987)). Similar concepts may apply in other contexts.

    [8] Question 260.23 states that “the reasonable care exception applies whenever … despite the exercise of reasonable care, [the issuer] could not have known that a disqualification existed under Rule 506(d)(1) … Issuers will still need to consider what steps are appropriate upon discovery of Rule 506(d) disqualifying events … throughout the course of an ongoing Rule 506 offering. An issuer may need to … provide Rule 506(e) disclosure, or take such other remedial steps to address the Rule 506(d) disqualification.”

    APPENDIX 1


    January 3, 2014 Compliance and Disclosure Interpretations Regarding Rule 506(d)Source: Division of Corporate Finance of the U.S. Securities and Exchange Commission

    Question 260.28 Is a shareholder that becomes a 20% beneficial owner by purchasing securities in an offering a covered person with respect to that offering?

    Answer: Rule 506(d) looks to the time of each sale of securities, and provides that no exemption will be available for the sale if any covered person is subject to a bad actor triggering event at that time. A shareholder that becomes a 20% beneficial owner upon completion of a sale of securities is not a 20% beneficial owner at the time of the sale. However, it would be a covered person with respect to any sales of securities in the offering that were made while it was a 20% beneficial owner.

    Question 260.29 Is the term “beneficial owner” in Rule 506(d) interpreted the same way as under Exchange Act Rule 13d-3?

    Answer: Yes, “beneficial owner” under Rule 506(d) means any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, under Exchange Act Rule 13d-3 has or shares, or is deemed to have or share: (1) voting power, which includes the power to vote, or to direct the voting of, such security; and/or (2) investment power, which includes the power to dispose, or to direct the disposition of, such security.

    Question 260.30 For purposes of determining 20% beneficial owners under Rule 506(d), is it necessary to “look through” entities to their controlling persons?

    Answer: Beneficial ownership includes both direct and indirect interests, determined as under Exchange Act Rule 13d-3.

    Question 260.31 Some of the shareholders of a Rule 506 issuer have entered into a voting agreement under which each shareholder agrees to vote its shares of voting equity securities in favor of director candidates designated by one or more of the other parties. Are the parties to the agreement required to aggregate their holdings for purposes of determining whether they as a group are, or any single party is, a 20% beneficial owner of the issuer and, therefore, a covered person under Rule 506(d)?

    Answer: Beneficial ownership of group members and groups should be analyzed the same as under Exchange Act Rules 13d-3 and 13d-5(b). Under that analysis, the shareholders have formed a group, and the group beneficially owns the shares beneficially owned by its members. In addition, the parties to the voting agreement that have or share the power to vote or direct the vote of shares beneficially owned by other parties to the agreement (through, for example, the receipt of an irrevocable proxy or the right to designate director nominees for whom the other parties have agreed to vote) will beneficially own such shares. Parties that do not have or share the power to vote or direct the vote of other parties’ shares would not beneficially own such shares solely as a result of entering into the voting agreement. See Exchange Act Sections 13(d) and 13(g) and Regulation 13D-G Beneficial Ownership Reporting CDI 105.06. If the group is a 20% beneficial owner, then disqualification or disclosure obligations would arise from court orders, injunctions, regulatory orders or other triggering events against the group itself. If a party to the voting agreement becomes a 20% beneficial owner because shares of other parties are added to its beneficial ownership, disqualification or disclosure obligations would arise from triggering events against that party.

    Question 260.32 Does an order issued by a court or regulator, in accordance with Rule 506(d)(2)(iii), waive the disclosure obligation set forth in Rule 506(e)?

    Answer: No. The disclosure obligation in Rule 506(e) pertains to an issuer’s obligation to provide investors disclosure of disqualifying events that would have triggered disqualification, except that these events occurred before September 23, 2013. Rule 506(d)(2)(iii) permits issuers to rely on the self-executing statement of a regulatory authority to avoid Rule 506 disqualification when that regulatory authority advises the Commission in writing or in its order, decree or judgment, that Rule 506 disqualification should not arise a consequence of a disqualifying event that occurred on or after September 23, 2013.

    A regulatory authority such as a state securities commission may, however, determine that an order entered before September 23, 2013 would not have triggered disqualification under Rule 506(d)(1) because the violation was not a final order based on a violation of any law or regulation that prohibits fraudulent, manipulative, or deceptive conduct entered within ten years before such sale.

    APPENDIX 2


    December 4, 2013 Compliance and Disclosure Interpretations Regarding Rule 506(d)Source: Division of Corporate Finance of the U.S. Securities and Exchange Commission

    Question 260.14 When is an issuer required to determine whether bad actor disqualification under Rule 506(d) applies?

    Answer: Rule 506(d) disqualifies an offering of securities from reliance on a Rule 506 exemption from Securities Act registration. Issuers must therefore determine if they are subject to bad actor disqualification any time they are offering or selling securities in reliance on Rule 506. An issuer that is not offering securities, such as a fund that is winding down and is closed to investment, need not determine whether Rule 506(d) applies unless and until it commences a Rule 506 offering. An issuer may reasonably rely on a covered person’s agreement to provide notice of a potential or actual bad actor triggering event pursuant to, for example, contractual covenants, bylaw requirements, or an undertaking in a questionnaire or certification. However, if an offering is continuous, delayed or long-lived, the issuer must update its factual inquiry periodically through bring-down of representations, questionnaires and certifications, negative consent letters, periodic re-checking of public databases, and other steps, depending on the circumstances.

    Question 260.15 If a placement agent or one of its covered control persons, such as an executive officer or managing member, becomes subject to a disqualifying event while an offering is still ongoing, could the issuer continue to rely on Rule 506 for that offering?

    Answer: Yes, the issuer could rely on Rule 506 for future sales in that offering if the engagement with the placement agent was terminated and the placement agent did not receive compensation for the future sales. Alternatively, if the triggering disqualifying event affected only the covered control persons of the placement agent, the issuer could continue to rely on Rule 506 for that offering if such persons were terminated or no longer performed roles with respect to the placement agent that would cause them to be covered persons for purposes of Rule 506(d).

    Question 260.16 For purposes of Rule 506(d), does an “affiliated issuer” mean every affiliate of the issuer that has issued securities?

    Answer: No. Under Rule 506(d), an “affiliated issuer” of the issuer is an affiliate (as defined in Rule 501(b) of Regulation D) of the issuer that is issuing securities in the same offering, including offerings subject to integration pursuant to Rule 502(a) of Regulation D. Securities Act Forms C&DIs 130.01 and 130.02 provide examples of co-issuer or multiple issuer offerings.

    Question 260.17 Are compensated solicitors limited to brokers, as defined in Exchange Act Section 3(a)(4), who are subject to registration pursuant to Exchange Act Section 15(a)(1), and their associated persons?

    Answer: No. All persons who have been or will be paid, directly or indirectly, remuneration for solicitation of purchasers are covered by Rule 506(d), regardless of whether they are, or are required to be, registered under Exchange Act Section 15(a)(1) or are associated persons of registered broker-dealers. The disclosure required in Item 12 of Form D expressly contemplates that compensated solicitors may not appear in FINRA’s Central Registration Depository (CRD) of brokers and brokerage firms.

    Question 260.18 Does the term “participating” include persons whose sole involvement with a Rule 506 offering is as members of a compensated solicitor’s deal or transaction committee that is responsible for approving such compensated solicitor’s participation in the offering?

    Answer: No.

    Question 260.19 Are officers of a compensated solicitor deemed to be “participating” in a Rule 506 offering only if they are involved with the solicitation of investors for that offering?

    Answer: No. Participation in an offering is not limited to solicitation of investors. Examples of participation in an offering include participation or involvement in due diligence activities or the preparation of offering materials (including analyst reports used to solicit investors), providing structuring or other advice to the issuer in connection with the offering, and communicating with the issuer, prospective investors or other offering participants about the offering. To constitute participation for purposes of the rule, such activities must be more than transitory or incidental. Administrative functions, such as opening brokerage accounts, wiring funds, and bookkeeping activities, would generally not be deemed to be participating in the offering.

    Question 260.20 Is disqualification under Rule 506(d) triggered by actions taken in jurisdictions other than the United States, such as convictions, court orders, or injunctions in a foreign court, or regulatory orders issued by foreign regulatory authorities?

    Answer: No.

    Question 260.21 Is disqualification under Rule 506(d)(1)(v) triggered by all Commission orders to cease and desist from violations of Commission rules promulgated under Exchange Act Section 10(b)?

    Answer: No. Disqualification is triggered only by orders to cease and desist from violations of scienter-based provisions of the federal securities laws, including scienter-based rules. An order to cease and desist from violations of a non-scienter based rule would not trigger disqualification, even if the rule is promulgated under a scienter-based provision of law. For example, an order to cease and desist from violations of Exchange Act Rule 105 would not trigger disqualification, even though Rule 105 is promulgated under Exchange Act Section 10(b).

    Question 260.22 If an order issued by a court or regulator provides, in accordance with Rule 506(d)(2)(iii), that disqualification from Rule 506 should not arise as a result of the order, is it necessary to seek a waiver from the Commission or to take any other action to confirm that bad actor disqualification will not apply as a result of the order?

    Answer: No. The provisions of Rule 506(d)(2)(iii) are self-executing.

    Question 260.23 Does the reasonable care exception only cover circumstances where the issuer has identified all covered persons but, despite the exercise of reasonable care, was unable to discover the existence of a disqualifying event? Or could it also apply where, despite the exercise of reasonable care, the issuer (i) was unable to determine that a particular person was a covered person (for example, an officer of a financial intermediary that the issuer did not know was participating in the offering, despite the exercise of reasonable care) or (ii) initially determined that the person was not a covered person but subsequently determined that the person should have been deemed a covered person?

    Answer: The reasonable care exception applies whenever the issuer can establish that it did not know and, despite the exercise of reasonable care, could not have known that a disqualification existed under Rule 506(d)(1). This may occur when, despite the exercise of reasonable care, the issuer was unable to determine the existence of a disqualifying event, was unable to determine that a particular person was a covered person, or initially reasonably determined that the person was not a covered person but subsequently learned that determination was incorrect. Issuers will still need to consider what steps are appropriate upon discovery of Rule 506(d) disqualifying events and covered persons throughout the course of an ongoing Rule 506 offering. An issuer may need to seek waivers of disqualification, terminate the relationship with covered persons, provide Rule 506(e) disclosure, or take such other remedial steps to address the Rule 506(d) disqualification.

    Question 260.24 Is there a procedure provided in Rule 506(e) for issuers to seek a waiver of the obligation to disclose past events that would have been disqualifying, except that they occurred before September 23, 2013 (the effective date of Rule 506(d))?

    Answer: No. The disclosure obligation is not subject to waiver.

    Question 260.25 Does Rule 506(e) require disclosure of past events that would no longer trigger disqualification under Rule 506(d), such as a criminal conviction that occurred more than ten years before the offering or an order or bar that is no longer in effect at the time of the offering?

    Answer: No. Rule 506(e) requires only disclosure of events that would have triggered disqualification at the time of the offering had Rule 506(d) been applicable. Because events outside the applicable look-back period and orders that do not have continuing effect would not trigger disqualification, Rule 506(e) does not mandate disclosure of such matters in order for the issuer to be able to rely on Rule 506.

    Question 260.26 In an offering in which the issuer uses multiple placement agents or other compensated solicitors, is the issuer required to provide investors with disclosure under Rule 506(e) only with respect to the particular compensated solicitor or placement agent that solicited those investors and its covered control persons (i.e., general partners, managing members, directors, executive officers, and other officers participating in the offering)?

    Answer: No. Issuers are required to provide all investors with the Rule 506(e) disclosure for all compensated solicitors who are involved with the offering at the time of sale and their covered control persons.

    Question 260.27 In a continuous offering, is the issuer required to provide disclosure under Rule 506(e) for all solicitors that were ever involved during the course of the offering?

    Answer: No. A reasonable time prior to the sale of securities in reliance on Rule 506, the issuer must provide the required disclosure with respect to all compensated solicitors that are involved at the time of sale. Disclosure with respect to compensated solicitors who are no longer involved with the offering need not be provided under Rule 506(e) in order for the issuer to be able to rely on Rule 506.


    This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • Your Skills: You Have a F/RAND Request

    ARTICLE

    Your Skills: You Have a F/RAND Request

    January 21, 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Demystifying the Sales Factor: Costs of Performance

    ARTICLE

    Demystifying the Sales Factor: Costs of Performance

    January 21, 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • CMS Proposed Rule Reflects Increased Sophistication in Administration of MA/Part D Programs

    CMS Proposed Rule Reflects Increased Sophistication in Administration of MA/Part D Programs

    ARTICLE / CLIENT ALERT

    CMS Proposed Rule Reflects Increased Sophistication in Administration of MA/Part D Programs

    January 21, 2014

    Read time: 12 min

    Key takeaways
    Overview

    Addressing issues ranging from participation in Part D Plan pharmacy networks to compliance training for so-called first-tier, downstream and related entities, the Proposed Rule covers numerous topics with varying degrees of importance for Medicare Advantage Organizations, Part D Plan Sponsors, pharmacy benefit managers, pharmacies, and other health care and administrative service providers.

    In depth

    The Centers for Medicare & Medicaid Services (CMS) on January 10, 2014, published the first “omnibus”-type proposed rule (Proposed Rule) for the Medicare Advantage (MA) and Medicare Prescription Drug (Part D) Programs in more than two years. Addressing issues ranging from participation in Part D Plan pharmacy networks to compliance training for so-called first-tier, downstream and related entities, the Proposed Rule covers numerous topics with varying degrees of importance for MA Organizations, Part D Plan Sponsors, pharmacy benefit managers, and other health care and administrative service providers participating in the Programs.

    This summary of the Proposed Rule addresses several issues of interest for both MA Organization and Part D Plan Sponsors (collectively, Plan Sponsors), as well as for entities with which Plan Sponsors contract. Other forthcoming On the Subjects will focus on CMS proposals for the Part D Program, risk adjustment data validation (RADV) proposals, and CMS’s proposed implementation of Section 6402 of the Affordable Care Act and its overpayment provisions for the MA and Part D Programs.

    Comments on the Proposed Rule are due to CMS by 5 p.m. EST on March 7, 2014.

    CMS Proposes Independent Program Audits at Plan Sponsors’ Expense

    CMS conducts annual performance audits of Plan Sponsors, but resources limit the number of its assessments. Accordingly, CMS proposes to adopt the authority to require Plan Sponsors to audit themselves. Plan Sponsors would be obligated to hire an independent auditor, at the Plan Sponsor’s expense, to undertake a performance audit in compliance with CMS standards and to report to CMS on deficiencies identified during the review. CMS’s authority also would include directing Plan Sponsors to engage independent auditors to verify corrective action undertaken by the Plan Sponsor to respond to any deficiencies identified in a performance audit.

    Several issues related to this proposal go unaddressed, including the qualifications for independent auditors, potential conflicts of interest between auditors and Plan Sponsors, and how CMS would ensure consistency among audits. In light of the fact that audit results factor into past performance reviews (affecting future Program participation opportunities) and quality star ratings (affecting MA Plan payments), and given the issues that have arisen during audits performed by CMS-contracted auditors, the lack of specific information regarding these self-auditing provisions potentially frustrates the ability of Plan Sponsors to provide meaningful comment on details that will be critical if this proposal is adopted.

    CMS estimates in the Proposed Rule that implementation of this independent auditing requirement would cost Plan Sponsors approximately $8.9 million every year. Given the complexity of the CMS requirements reviewed through program audits, the high cost of consulting and audit firms with specialization in this field, and the internal resources Plan Sponsors will have to dedicate to facilitating these audits, it is possible that the ultimate costs to the industry could be much higher.

    Revised Compensation Formula for Agents and Brokers May Decrease Renewal Payments

    CMS proposes to revise the independent agent/broker compensation regulations, in part to further minimize incentives to move Medicare beneficiaries among MA and Part D Plans. To date, Plan Sponsors must limit compensation for initial and renewal enrollments in their MA/Part D Plans to amounts that are equal to or less than the fair market value (FMV) amount adopted by CMS for initial enrollments, or 50 percent thereof for renewals through the sixth renewal year. To simplify the requirements, CMS would retain the existing FMV ceiling on compensation for initial enrollments, but would reduce the renewal compensation ceiling to up to 35 percent of the FMV, if renewal compensation is paid by the Plan Sponsor. CMS also removed the six-year compensation cycle requirement, such that agents and brokers may be paid for enrollee renewals indefinitely.

    Under the Proposed Rule, the referral fee parameters previously articulated by CMS in sub-regulatory guidance—in particular, the requirement that such payment be included in the determination of compensation paid in connection with a beneficiary’s enrollment and subject to the regulatory limits—would be incorporated into regulation.

    Next Steps

    Plan Sponsors that rely on independent agents and brokers for marketing and enrollment activities may consider evaluating their programs, contracts and other operations that would be affected if CMS finalizes these proposals, in order to come into compliance prior to the launch of CY 2015 marketing on October 1, 2014.

    Standardized Compliance Program Training for FDRs Does Not Relieve Administrative Burdens

    Plan Sponsors are required to maintain “effective compliance programs,” which must include mandatory training and education on the Plan Sponsors’ compliance programs for first-tier, downstream and related entities (FDRs). Plan Sponsors have typically implemented this requirement through Plan Sponsor-specific compliance training obligations, which CMS has acknowledged on several occasions poses challenges for health care providers and other entities that contract with multiple Plan Sponsors and therefore must complete multiple compliance training programs. Accordingly, CMS proposes to amend the regulatory requirement, obligating the Plan Sponsor to require all FDRs to take CMS’s standardized compliance training and accept the certificate of completion of such training. Under the Proposed Rule, this CMS training would no longer be an option for satisfying the training requirement but in fact would be the only way. Plan Sponsors would be prohibited from providing Plan Sponsor-specific training in fulfillment of this requirement.

    Although the standardized CMS training module may reduce the training burden for providers and other FDRs, Plan Sponsors may not see the same benefits. Plan Sponsors would, for example, continue to be required to maintain “effective” compliance programs, and a general CMS compliance training may undermine the effectiveness of a compliance program that reflects a Plan Sponsor’s specific operations, standards and protocols. Moreover, CMS proposes to retain the obligation for Plan Sponsors to track FDRs’ completion of this CMS training, to maintain supporting documentation in the event of a CMS audit, and to negotiate a contractual provision in connection with the same. FDRs similarly would remain obligated to provide multiple Plan Sponsors with documentation of CMS compliance training completion.

    Further, this proposed change arguably transforms the compliance training component into more of a direct Medicare Program requirement imposed by CMS, rather than an MA or Part D Program requirement reflecting the unique characteristics of the Programs or the Plan Sponsors. Although it would be reasonable for Plan Sponsors to administer a compliance training requirement (and collect documentation) for administrative service providers and other entities that are not participating providers in the Medicare Program and do not contract with CMS, it is less clear why Plan Sponsors—and not CMS or its Medicare Administrative Contractors—should administer a Medicare compliance training obligation, particularly since these providers also undergo CMS fraud and abuse training as part of their Original Medicare enrollment.

    Also of interest is CMS’s proposal to adopt a new definition for the MA Program for the term “parent organization,” in connection with the agency’s proposal to limit new enrollment in certain cost contracts. CMS does not, however, reference in the Proposed Rule the fact that the term “parent organization” is used in other agency guidance, such as Chapters 9 and 21 of the Prescription Drug Benefit Manual and Medicare Managed Care Manual, respectively, nor reconcile this definition with the existing definition of “related entity.” This proposed definition and its lack of coordination with other terms and requirements potentially could create challenges for Plan Sponsors with multiple legal entities in their corporate enterprise.

    Next Steps

    Plan Sponsors, providers and other FDRs may consider submitting to CMS information and data describing the administrative burden associated with the current compliance training obligations and the revised approach, to help educate CMS on the burdens that would be eliminated—and those that would remain—under the proposal. Tracking CMS’s final action in this area will be important for updating compliance programs and FDR contracts.

    More Changes, Including Business Continuity Obligations, for FDR Contracts?

    CMS continues to tinker with FDR contract requirements, setting out in the Proposed Rule an amendment to the record retention and access provision that would provide the U.S. Department of Health & Human Services, the Comptroller General or their designees with the right to audit, evaluate, collect and inspect directly an FDR’s records. The Plan Sponsor would not be permitted to play an intermediary role in facilitating the request for and provision of records between the government and the Plan Sponsor’s contractor, notwithstanding the fact that it is the Plan Sponsor’s contract with CMS that serves as the basis for CMS seeking the FDR’s records. Rather, CMS indicates in the preamble (but not the regulatory text) that it would provide notice to the Plan Sponsor of any record request.

    A separate proposal would impose new requirements for Plan Sponsors’ business continuity plans, including obligations related to risk assessments, mitigation strategies, annual testing, training and documentation. Among the requirements is an obligation for Plan Sponsors to restore “essential functions” within 24 hours after any of the functions fail or stop functioning as usual. An MA Organization’s and a Part D Plan Sponsor’s respective “essential functions” are identified in the Proposed Rule, and include benefit authorization and claims adjudication, call centers, and organization/coverage determinations and appeals. Plan Sponsors that delegate any of these functions likely will have to revisit their contracts, particularly the performance standards, to address any finalized requirements applicable to the FDR. Coordination of the operational elements of Plan Sponsors’ business recovery processes with that of their FDRs also may be an important consideration if CMS moves forward with this requirement.

    Next Steps

    If finalized, several proposals in the Proposed Rule may require FDRs’ cooperation for implementation, and Plan Sponsors likely will not have the resources to modify all contracts immediately. Identifying now the contracts that should be a high priority for review upon release of final regulations—such as those under negotiation or coming up for renewal, and key service arrangements—may help streamline the contracting process and apply resources effectively and efficiently. To the extent their contracts do not already do so, Plan Sponsors may consider whether and how to modify FDR contracts to protect Plan Sponsors’ ability to learn about any government audit of an FDR that relates to the Plan Sponsors’ MA/Part D contracts with CMS, and to know what information is collected, now that Plan Sponsors may not contractually preserve their right to serve as the go-between.

    Revised Participation Criteria for MA and Part D Programs

    The Proposed Rule exemplifies CMS’s continued trend of managing—indeed, limiting—the entities permitted to participate in the MA and Part D Programs under the banner of protecting Medicare beneficiaries. The following are some examples:

    • CMS proposes to require that entities applying to become Part D Plan Sponsors (whether as an MA Organization offering a Medicare Advantage-Prescription Drug Plan or stand-alone Part D Plan) must have (or have an affiliate that has) at least one full benefit year of experience performing key Part D functions, or have contracted with an FDR that has such experience, within the two years prior to the application deadline.
    • CMS also proposes implementing an “essential operations test” as a new step in the Plan Sponsor application process for entities that are new to the Part D Program. This test, performed post-application and post-bidding, would assess the ability of applicants to actually perform the required operational functions of a Part D Plan prior to the January 1 launch date of the benefit plan.
    • CMS also proposes to prohibit applications from entities that apply to become a stand-alone Part D Plan Sponsor but withdraw their applications and bids following release of the low-income subsidy benchmark (and prior to finalization of the contract with CMS). This new requirement is intended to prevent gaming of the competitive bidding system.

    Next Steps

    These provisions would not be finalized in time for the CY 2015 applications process, but would apply to the CY 2016 application cycle, if finalized. Organizations that are considering applying to participate in the MA and Part D Programs—alone or through a joint venture with another party—may need to evaluate their strategic plans and partners to accommodate new participation requirements.

    Other Proposed Regulatory Changes

    • CMS has proposed regulations to codify its new authority, under Section 6408 of the Affordable Care Act, to impose sanctions on a Plan Sponsor that enrolls an individual or transfers an individual to a new Plan without prior consent (except in limited circumstances). The statute and these proposed regulations also make it a contract violation for a Plan Sponsor to violate the Part C and D marketing requirements or to employ or contract with any individual or entity that engages in any of the conduct that gives CMS the right to impose intermediate sanctions (as set forth in Section 1857(g) of the Social Security Act).
    • CMS proposes several modifications to the intermediate sanction and civil money penalty (CMP) provisions, including expanding the bases upon which CMS may impose CMPs.
    • CMS proposes to shorten to 45 days the advance notice it provides before terminating an MA or Part D Plan contract.
    • CMS proposes an administrative appeals process for appealing Part C and Part D Recovery Audit Contractor (RAC) overpayment determinations. Under the proposal, Plan Sponsors would be permitted to appeal only a RAC’s application of the prescribed payment methodology, and not the underlying payment methodology itself. The proposed three-step appeals process, which involves a reconsideration phase, appeal to a hearing officer and discretionary review by the CMS Administrator, was modeled after the existing RADV audit dispute and appeals process.

    Conclusion

    The Proposed Rule continues CMS’s trend over the past several years to enhance its ability to administer the MA and Part D Programs, as well as to expand and tighten the performance requirements for Program participants. The increase in performance audits and proposal for self-auditing, as well as CMS’s willingness to impose sanctions and CMPs on Plan Sponsors that do not meet the performance standards, ups the ante for Program participants.

    Authors
    More insights

  • Increased HSR Act Thresholds Announced for 2014

    Increased HSR Act Thresholds Announced for 2014

    ARTICLE / CLIENT ALERT

    Increased HSR Act Thresholds Announced for 2014

    January 21, 2014

    Read time: 2 min

    Key takeaways
    Overview

    The Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended, the “HSR Act”) requires parties to acquisitions of voting securities, assets or non-corporate interests meeting certain thresholds to make a premerger notification to the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of Justice, and to observe a waiting period prior to consummating such acquisitions. On Jan. 17, 2014, the FTC announced its annual adjustments to the current HSR Act thresholds. Any transaction that will be consummated on or after the Feb. 24, 2014 effective date may be reportable under the HSR Act if, as a result of such transaction, the acquiring person will hold voting securities, assets and/or non-corporate interests of the acquired person valued above $75.9 million (the current adjusted minimum threshold is $70.9 million). The new adjusted thresholds reflect changes in the gross national product for the preceding fiscal year.

    In depth
    Authors

    Peter Jonathan Halasz

    Of Counsel

    New York – 919 Third Avenue

    More insights

  • Obtaining Information from the Government – Disclosure Statutes (Portfolio 625-2nd)

    ARTICLE

    Obtaining Information from the Government – Disclosure Statutes (Portfolio 625-2nd)

    January 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Incalculable Risk of Liability GmbH of a Managing Director at Shield or Safety of Self-Administration?

    ARTICLE

    Incalculable Risk of Liability GmbH of a Managing Director at Shield or Safety of Self-Administration?

    January 14, 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Deciding on Arbitrability in International Arbitrations

    ARTICLE

    Deciding on Arbitrability in International Arbitrations

    January 14, 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Code Sec. 956 Traps

    ARTICLE

    Code Sec. 956 Traps

    January – February 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • ABA 2013 Annual Broker-Dealer Survey

    ARTICLE

    ABA 2013 Annual Broker-Dealer Survey

    January 2014

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights